Načítá se...

Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains

The characterization of kinases as oncogenic drivers has led to more than 30 FDA-approved targeted kinase inhibitors for cancer treatment. Unfortunately, these therapeutics fail to have clinical durability because of adaptive responses from the kinome and transcriptome that bypass inhibition of the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cell Oncol
Hlavní autoři: Stuhlmiller, Timothy J., Miller, Samantha M., Johnson, Gary L.
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2015
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4845204/
https://ncbi.nlm.nih.gov/pubmed/27308566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2015.1052182
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!